Switch theme
Sign up to access all valuation multiples
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
2000
206
LTM Revenue $53.3M
LTM EBITDA -$46.4M
$121M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
CVRx has a last 12-month revenue (LTM) of $53.3M and a last 12-month EBITDA of -$46.4M.
In the most recent fiscal year, CVRx achieved revenue of $51.3M and an EBITDA of -$54.9M.
CVRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See CVRx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $53.3M | XXX | $51.3M | XXX | XXX | XXX |
| Gross Profit | $44.6M | XXX | $43.0M | XXX | XXX | XXX |
| Gross Margin | 84% | XXX | 84% | XXX | XXX | XXX |
| EBITDA | -$46.4M | XXX | -$54.9M | XXX | XXX | XXX |
| EBITDA Margin | -87% | XXX | -107% | XXX | XXX | XXX |
| EBIT | -$55.7M | XXX | -$59.5M | XXX | XXX | XXX |
| EBIT Margin | -104% | XXX | -116% | XXX | XXX | XXX |
| Net Profit | -$56.8M | XXX | -$60.0M | XXX | XXX | XXX |
| Net Margin | -107% | XXX | -117% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, CVRx's stock price is $7.
CVRx has current market cap of $173M, and EV of $121M.
See CVRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $121M | $173M | XXX | XXX | XXX | XXX | $-2.38 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, CVRx has market cap of $173M and EV of $121M.
CVRx's trades at 2.4x EV/Revenue multiple, and -2.2x EV/EBITDA.
Equity research analysts estimate CVRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
CVRx has a P/E ratio of -3.0x.
See valuation multiples for CVRx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $173M | XXX | $173M | XXX | XXX | XXX |
| EV (current) | $121M | XXX | $121M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.4x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.2x | XXX | XXX | XXX |
| EV/EBIT | -2.2x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | 2.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.0x | XXX | -2.9x | XXX | XXX | XXX |
| EV/FCF | -3.4x | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCVRx's last 12 month revenue growth is 13%
CVRx's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
CVRx's rule of 40 is -85% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
CVRx's rule of X is -54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for CVRx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 13% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Margin | -87% | XXX | -107% | XXX | XXX | XXX |
| EBITDA Growth | -12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -85% | XXX | -94% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 22% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 200% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
CVRx acquired XXX companies to date.
Last acquisition by CVRx was XXXXXXXX, XXXXX XXXXX XXXXXX . CVRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was CVRx founded? | CVRx was founded in 2000. |
| Where is CVRx headquartered? | CVRx is headquartered in United States of America. |
| How many employees does CVRx have? | As of today, CVRx has 206 employees. |
| Who is the CEO of CVRx? | CVRx's CEO is Mr. Kevin Hykes, M.B.A.. |
| Is CVRx publicy listed? | Yes, CVRx is a public company listed on NAS. |
| What is the stock symbol of CVRx? | CVRx trades under CVRX ticker. |
| When did CVRx go public? | CVRx went public in 2021. |
| Who are competitors of CVRx? | Similar companies to CVRx include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of CVRx? | CVRx's current market cap is $173M |
| What is the current revenue of CVRx? | CVRx's last 12 months revenue is $53.3M. |
| What is the current revenue growth of CVRx? | CVRx revenue growth (NTM/LTM) is 13%. |
| What is the current EV/Revenue multiple of CVRx? | Current revenue multiple of CVRx is 2.3x. |
| Is CVRx profitable? | Yes, CVRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of CVRx? | CVRx's last 12 months EBITDA is -$46.4M. |
| What is CVRx's EBITDA margin? | CVRx's last 12 months EBITDA margin is -87%. |
| What is the current EV/EBITDA multiple of CVRx? | Current EBITDA multiple of CVRx is -2.6x. |
| What is the current FCF of CVRx? | CVRx's last 12 months FCF is -$35.9M. |
| What is CVRx's FCF margin? | CVRx's last 12 months FCF margin is -67%. |
| What is the current EV/FCF multiple of CVRx? | Current FCF multiple of CVRx is -3.4x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
